Skip to main content

Advertisement

Table 1 Comparison of clinical features between breast tumors associated or not with L3MBTL4 loss (determined by aCGH)

From: Loss, mutation and deregulation of L3MBTL4 in breast cancers

Characteristics (N) L3MBTL4 non deleted L3MBTL4 deleted p odds ratio
  N = 230 N = 77   
Age (300) 52 (22-84) 51 (24-82) 0.69  
Histological type (255)    0.57  
Ductal 152 (78%) 48 (79%)   
Lobular 15 (8%) 5 (8%)   
Medularry 12 (6%) 2 (3%)   
Mixt 8 (4%) 3 (5%)   
Other 7(4%) 3 (5%)   
Clinical form (301)    0.11 1.76
IBC 33 (15%) 18 (23%)   (0.87-3.5)
Non IBC 191 (85%) 59 (77%)   
Pathological tumor size (240)    0.052  
pT1 45 (25%) 8 (14%)   
pT2 95 (52%) 28 (48%)   
pT3 42 (23%) 22 (38%)   
Pathological axillary lymph node status (266)    1.02E-02 0.46
Negative 96 (48%) 20 (30%)   (0.24-0.85)
Positive 103 (52%) 47 (70%)   
SBR grade (267)    1.15E-02  
1 38 (19%) 3 (5%)   
2 63 (31%) 25 (38%)   
3 100 (50%) 38 (58%)   
ER (275)    0.11 0.6
Negative 84 (40%) 19 (29%)   (0.31-1.13)
Positive 125 (60%) 47 (71%)   
PR (264)    0.32 0.74
Negative 96 (48%) 26 (41%)   (0.4-1.36)
Positive 104 (52%) 38 (59%)   
P53 (192)    0.39 1.38
Negative 87 (59%) 30 (67%)   (0.65-3)
Positive 60 (41%) 15 (33%)   
Ki67 (217)    0.23 0.64
Negative 53 (32%) 12 (23%)   (0.28-1.36)
Positive 112 (68%) 40 (77%)   
ERBB2 (226)    1 1.03
Negative 145 (85%) 48 (86%)   (0.42-2.83)
Positive 25 (15%) 8 (14%)   
Molecular subtype (264)    8.04E-04  
Basal 63 (33%) 17 (23%)   
ERBB2 22 (12%) 9 (12%)   
Luminal A 52 (27%) 18 (25%)   
Luminal B 29 (15%) 27 (37%)   
Normal-like 25 (13%) 2 (3%)   
Metastatic relapse (198)    0.32 0.62
no 135 (88%) 37 (82%)   (0.23-1.78)
yes 18 (12%) 8 (18%)   
Death from breast cancer (239)    0.38 0.73
no 139 (77%) 41 (71%)   (0.36-1.52)
yes 42 (23%) 17 (29%)   
5 year-Metastasis-free survival (198) 90% 81% 0.254  
5 year-Overall specific survival (239) 78% 73% 0.271  
  1. Note: IBC, Inflammatory Breast Cancer; SBR, Scarf-Bloom-Richardson, histological grade.